Clinical Trial Update: First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases [Phase 1]

View source ↗

Summary

First-in-human Phase 1 dose trial for a new liver-disease medication from Novo Nordisk has completed initial dosing in healthy volunteers and individuals with h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Steatosis

Drugs mentioned

• Investigational drug (name not disclosed)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Healthy Volunteers, Hepatic Steatosis | Phase 1 | Status: COMPLETED